Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease
| Autor: | Milène Vandal, Fabien Pifferi, Jennifer Tremblay-Mercier, Stephen C. Cunnane, Mélanie Fortier, Michel E. Bégin, Mélanie Plourde, Erika Freemantle |
|---|---|
| Přispěvatelé: | Centre de recherche du centre hospitalier de l'Université Laval (CHUQ), Centre Hospitalier de Laval (CH Laval), Mécanismes adaptatifs : des organismes aux communautés (MAOAC), Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Docosahexaenoic Acids genetic structures [SDV]Life Sciences [q-bio] Clinical Biochemistry Population Disease Biology 03 medical and health sciences Cognition 0302 clinical medicine Degenerative disease Alzheimer Disease Internal medicine medicine Animals Humans Cognitive decline education Phospholipids ComputingMilieux_MISCELLANEOUS Unsaturated fatty acid 030304 developmental biology chemistry.chemical_classification 0303 health sciences education.field_of_study Brain food and beverages Cell Biology medicine.disease 3. Good health Endocrinology Biochemistry chemistry Docosahexaenoic acid lipids (amino acids peptides and proteins) Cholesterol Esters Alzheimer's disease 030217 neurology & neurosurgery Polyunsaturated fatty acid |
| Zdroj: | Prostaglandins, Leukotrienes and Essential Fatty Acids Prostaglandins, Leukotrienes and Essential Fatty Acids, Elsevier, 2007, 77 (5-6), pp.301-308. ⟨10.1016/j.plefa.2007.10.024⟩ Prostaglandins, Leukotrienes and Essential Fatty Acids, 2007, 77 (5-6), pp.301-308. ⟨10.1016/j.plefa.2007.10.024⟩ |
| ISSN: | 0952-3278 |
| Popis: | Lower consumption of docosahexaenoic acid (DHA) is commonly but not always associated with higher risk of cognitive decline and diagnosis of Alzheimer's disease (AD). We review here the available data relating DHA to AD, with emphasis on DHA content of plasma and brain. Our assessment of this literature is that low DHA is not consistently observed in AD plasma or brain. However, in dietary and population studies, low DHA intake is usually associated with low plasma DHA. Therefore, at present, there is no clear explanation of why the usual low DHA intake-low plasma DHA relationship appears not to exist in AD. Adding to the confusion, preliminary and inconclusive reports tentatively suggest that dietary DHA could potentially reduce cognitive deterioration in AD. These inconsistencies between dietary DHA, plasma/tissue DHA, and possible DHA efficacy in AD may be more methodological than biological, and may arise in part because only one study to date has reported both DHA intake and plasma DHA values in the same AD patients. Studies reporting DHA intake and plasma levels while also undertaking a DHA intervention in AD would presumably help resolve these issues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect